This “Locally Advanced Pancreatic Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Locally Advanced Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Locally Advanced Pancreatic Cancer Understanding
Locally advanced pancreatic cancer (LAPC) is a non-metastasized pancreatic cancer, in which upfront resection is considered not beneficial due to extensive vascular involvement and consequent high chance of a non-radical resection. Locally advanced pancreatic cancer is typically associated with patients in stage 3 of the disease as determined by the TNM (tumor, nodes and metastasis) grading system. Although locally advanced pancreatic cancer has a poor prognosis, it is clearly better than that of metastatic disease, with a median survival of 9 months compared with the 3-month survival of the metastatic disease. Treatments for locally advanced pancreatic cancer includes chemotherapy, radiation therapy, and surgery. FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) has had major implications for the management and outcome of patients with LAPC.
"Locally Advanced Pancreatic Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Locally Advanced Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Locally Advanced Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Locally Advanced Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Locally Advanced Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Locally Advanced Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Locally Advanced Pancreatic Cancer.
This segment of the Locally Advanced Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pamrevlumab is a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), which promotes muscle fibrosis and reduces the ability of damaged muscle cells to repair. Pamrevlumab binds to CTGF and may prevent this cascade. Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC).
BEY1107 is a small molecule based CDK1 inhibitor. BEY1107 induces apoptosis through cell suicide mechanism by synchronizing cell cycles to G2 / M phase of pancreatic cancer cells. In addition, BEY1107P suppresses the mobility and invasiveness of pancreatic cancer cells and inhibits the self-renewal of cancer stem cells, demonstrating effectiveness as a monotherapy as well. In particular, when combined with the cytotoxic anti-cancer drug Gemcitabine, BEY1107P is expected to overcome the resistance developed from Gemcitabine. The drug is in Phase I/II clinical development for the treatment of Locally Advanced or Metastatic Pancreatic Cancer.
This segment of the report provides insights about the different Locally Advanced Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 12+ key companies which are developing the therapies for Locally Advanced Pancreatic Cancer. The companies which have their Locally Advanced Pancreatic Cancer drug candidates in the most advanced stage, i.e. Preregistration include, FibroGen.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Locally Advanced Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Locally Advanced Pancreatic Cancer drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Locally Advanced Pancreatic Cancer Understanding
Locally Advanced Pancreatic Cancer: Overview
Locally advanced pancreatic cancer (LAPC) is a non-metastasized pancreatic cancer, in which upfront resection is considered not beneficial due to extensive vascular involvement and consequent high chance of a non-radical resection. Locally advanced pancreatic cancer is typically associated with patients in stage 3 of the disease as determined by the TNM (tumor, nodes and metastasis) grading system. Although locally advanced pancreatic cancer has a poor prognosis, it is clearly better than that of metastatic disease, with a median survival of 9 months compared with the 3-month survival of the metastatic disease. Treatments for locally advanced pancreatic cancer includes chemotherapy, radiation therapy, and surgery. FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) has had major implications for the management and outcome of patients with LAPC.
"Locally Advanced Pancreatic Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Locally Advanced Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Locally Advanced Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Locally Advanced Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Locally Advanced Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Locally Advanced Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Locally Advanced Pancreatic Cancer.
Locally Advanced Pancreatic Cancer Emerging Drugs Chapters
This segment of the Locally Advanced Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Locally Advanced Pancreatic Cancer Emerging Drugs
Pamrevlumab: FibroGen
Pamrevlumab is a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), which promotes muscle fibrosis and reduces the ability of damaged muscle cells to repair. Pamrevlumab binds to CTGF and may prevent this cascade. Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC).
BEY1107: BeyondBio
BEY1107 is a small molecule based CDK1 inhibitor. BEY1107 induces apoptosis through cell suicide mechanism by synchronizing cell cycles to G2 / M phase of pancreatic cancer cells. In addition, BEY1107P suppresses the mobility and invasiveness of pancreatic cancer cells and inhibits the self-renewal of cancer stem cells, demonstrating effectiveness as a monotherapy as well. In particular, when combined with the cytotoxic anti-cancer drug Gemcitabine, BEY1107P is expected to overcome the resistance developed from Gemcitabine. The drug is in Phase I/II clinical development for the treatment of Locally Advanced or Metastatic Pancreatic Cancer.
Locally Advanced Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Locally Advanced Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Locally Advanced Pancreatic Cancer
There are approx. 12+ key companies which are developing the therapies for Locally Advanced Pancreatic Cancer. The companies which have their Locally Advanced Pancreatic Cancer drug candidates in the most advanced stage, i.e. Preregistration include, FibroGen.
Phases
This report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Locally Advanced Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Locally Advanced Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Locally Advanced Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Locally Advanced Pancreatic Cancer drugs.
Locally Advanced Pancreatic Cancer Report Insights
- Locally Advanced Pancreatic Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Locally Advanced Pancreatic Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Locally Advanced Pancreatic Cancer drugs?
- How many Locally Advanced Pancreatic Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Locally Advanced Pancreatic Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Locally Advanced Pancreatic Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Locally Advanced Pancreatic Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Scandion Oncology
- FibroGen
- RenovoRx
- BeyondBio
- Sun Pharmaceutical Industries
- AstraZeneca
- Silenseed
- ImmunityBio
- NanOlogy
Key Products
- SCO-101
- Pamrevlumab
- Gemcitabine
- BEY1107
- Sonidegib
- Ceralasertib
- siG12D-LODER
- Inbakicept
- NanoPac
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Locally Advanced Pancreatic Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Locally Advanced Pancreatic Cancer - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Pamrevlumab: FibroGen
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
siG12D-LODER: Silenseed
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
BEY1107: BeyondBio
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Locally Advanced Pancreatic Cancer Key Companies
Locally Advanced Pancreatic Cancer Key Products
Locally Advanced Pancreatic Cancer- Unmet Needs
Locally Advanced Pancreatic Cancer- Market Drivers and Barriers
Locally Advanced Pancreatic Cancer- Future Perspectives and Conclusion
Locally Advanced Pancreatic Cancer Analyst Views
AppendixList of Tables
Table 1 Total Products for Locally Advanced Pancreatic Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Locally Advanced Pancreatic Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Scandion Oncology
- FibroGen
- RenovoRx
- BeyondBio
- Sun Pharmaceutical Industries
- AstraZeneca
- Silenseed
- ImmunityBio
- NanOlogy
